Suppr超能文献

不断演变的格局:转移性结直肠癌的新疗法。

An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer.

机构信息

Department of Oncology, Montefiore Einstein, Bronx, NY; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.

Department of Oncology, Montefiore Einstein, Bronx, NY; Department of Molecular Pharmacology, Montefiore Einstein, Bronx, NY.

出版信息

Clin Colorectal Cancer. 2024 Dec;23(4):337-345. doi: 10.1016/j.clcc.2024.08.003. Epub 2024 Aug 24.

Abstract

Substantial progress is being made in the development of novel therapies directed against colorectal cancer. The discovery of various molecular markers and advances in tumor profiling have facilitated the development of new targeted agents and immunotherapy. Not only have these drugs improved progression-free survival and even overall survival in some cases, but their related outcomes have also raised questions as to how to best combine or sequence therapies for even greater efficacy. Furthermore, we are beginning to understand how these combination therapies may yield for greater therapeutic response for patients with microsatellite stable colorectal cancer for which there is much need for improvement. In this article, we review recent trial data and explore the outcomes of various targeted therapies and immunotherapies for patient with advanced colorectal cancer.

摘要

针对结直肠癌的新型治疗方法正在取得重大进展。各种分子标志物的发现和肿瘤分析技术的进步促进了新型靶向药物和免疫疗法的发展。这些药物不仅在某些情况下改善了无进展生存期,甚至总生存期,而且其相关结果也提出了如何最好地组合或序贯治疗以获得更大疗效的问题。此外,我们开始了解这些联合疗法如何为微卫星稳定型结直肠癌患者带来更大的治疗反应,而这些患者非常需要改善。在本文中,我们回顾了最近的试验数据,并探讨了各种针对晚期结直肠癌患者的靶向治疗和免疫治疗的结果。

相似文献

1
An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer.
Clin Colorectal Cancer. 2024 Dec;23(4):337-345. doi: 10.1016/j.clcc.2024.08.003. Epub 2024 Aug 24.
2
Advancements in combining targeted therapy and immunotherapy for colorectal cancer.
Trends Cancer. 2024 Jul;10(7):598-609. doi: 10.1016/j.trecan.2024.05.001. Epub 2024 May 31.
3
Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
Trends Cancer. 2024 Dec;10(12):1093-1094. doi: 10.1016/j.trecan.2024.10.006. Epub 2024 Oct 24.
6
Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
Int Immunopharmacol. 2021 Oct;99:108017. doi: 10.1016/j.intimp.2021.108017. Epub 2021 Aug 2.
7
Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
NEJM Evid. 2024 Jun;3(6):EVIDra2300353. doi: 10.1056/EVIDra2300353. Epub 2024 May 28.
8
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
9
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Curr Treat Options Oncol. 2016 Aug;17(8):41. doi: 10.1007/s11864-016-0414-4.

本文引用的文献

1
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.
N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26.
2
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Cancer Discov. 2024 Jun 3;14(6):982-993. doi: 10.1158/2159-8290.CD-24-0217.
4
Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.
Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4.
5
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
6
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Oncogene. 2023 Oct;42(44):3252-3259. doi: 10.1038/s41388-023-02835-y. Epub 2023 Sep 21.
8
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Oncoimmunology. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169. eCollection 2023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验